Single‐gene assays are also frequently still employed to inform timely clinical decisions for gene targets requiring rapid turnaround times (TAT), such as FLT3, IDH1, IDH2, and NPM1 at the time of AML diagnosis, when the TAT of NGS does not meet clinical needs. Here, NPM1 is linked to acute myeloid leukemia.